Work

Isa-VRd Improves Outcomes in High-Risk Newly Diagnosed Transplant-Ineligible Multiple Myeloma Using the IMS/IMWG Consensus HR Definition: Results from the BENEFIT Phase 3 Trial (IFM 2020–05)

Year: 2025

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(25)03843-1

Authors: Jill Corre, Jerome Lambert, Arthur Bobin, Salomon Manier, Aurore Perrot, Lionel Karlin, Kamel Laribi, Laurent Frenzel, Olivier Decaux, Bertrand Arnulf, Karim Belhadj Merzoug, Anais Schavgoulidze, Cyrille Touzeau, Mohamad Mohty, Philippe Moreau, Thierry Facon, Cyrille Hulin, Xavier Leleu

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4414302907

FWCI: 0.739

Cites:

Cited by: 1

Related to: 10